NexImmune Analyst Ratings
NexImmune Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/16/2022 | 138.1% | Raymond James | $12 → $3 | Maintains | Outperform |
06/01/2022 | 296.83% | BTIG | → $5 | Initiates Coverage On | → Buy |
04/01/2022 | 455.56% | Barclays | $4 → $7 | Maintains | Overweight |
02/22/2022 | 931.75% | Raymond James | $21 → $13 | Maintains | Outperform |
11/15/2021 | 1566.67% | Raymond James | $30 → $21 | Maintains | Outperform |
04/01/2021 | 2280.95% | Raymond James | → $30 | Initiates Coverage On | → Outperform |
03/09/2021 | 2677.78% | Cantor Fitzgerald | → $35 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
08/16/2022 | 138.1% | 雷蒙德·詹姆 | 12 美元 → 3 美元 | 維護 | 跑贏大盤 |
2022 年 1 月 6 日 | 296.83% | BTIG | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
04/01/2022 | 455.56% | 巴克萊 | 4 美元 → 7 美元 | 維護 | 超重 |
02/22/2022 | 931.75% | 雷蒙德·詹姆 | 21 美元 → 13 美元 | 維護 | 跑贏大盤 |
11/15/2021 | 1566.67% | 雷蒙德·詹姆 | 30 美元 → 21 美元 | 維護 | 跑贏大盤 |
2021 年 1 月 4 日 | 2280.95% | 雷蒙德·詹姆 | → 30 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2021 年 9 月 3 日 | 2677.78% | 坎託·菲茨傑拉德 | → 35 美元 | 啓動覆蓋範圍開啓 | → 超重 |
NexImmune Questions & Answers
nexImmune 問答
The latest price target for NexImmune (NASDAQ: NEXI) was reported by Raymond James on August 16, 2022. The analyst firm set a price target for $3.00 expecting NEXI to rise to within 12 months (a possible 138.10% upside). 5 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯於2022年8月16日公佈了NexImmune(納斯達克股票代碼:NEXI)的最新目標股價。該分析公司將目標股價定爲3.00美元,預計NEXI將在12個月內升至12個月內(可能上漲138.10%)。去年有5家分析公司公佈了評級。
The latest analyst rating for NexImmune (NASDAQ: NEXI) was provided by Raymond James, and NexImmune maintained their outperform rating.
雷蒙德·詹姆斯對NexImmune(納斯達克股票代碼:NEXI)的最新分析師評級由雷蒙德·詹姆斯提供,NexImmune維持跑贏大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NexImmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NexImmune was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與NexImmune的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。NexImmune 的最新評級是在 2022 年 8 月 16 日公佈的,因此您應該預計,下一個評級將在 2023 年 8 月 16 日左右公佈。
While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a maintained with a price target of $12.00 to $3.00. The current price NexImmune (NEXI) is trading at is $1.26, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的NexImmune(NEXI)評級保持不變,目標股價爲12.00美元至3.00美元。NexImmune(NEXI)目前的交易價格爲1.26美元,超出了分析師的預期區間。